0001237899-20-000010.txt : 20200214
0001237899-20-000010.hdr.sgml : 20200214
20200214161051
ACCESSION NUMBER: 0001237899-20-000010
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200213
FILED AS OF DATE: 20200214
DATE AS OF CHANGE: 20200214
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Tessier-Lavigne Marc
CENTRAL INDEX KEY: 0001437435
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-19034
FILM NUMBER: 20619772
MAIL ADDRESS:
STREET 1: 1 DNA WAY
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: REGENERON PHARMACEUTICALS, INC.
CENTRAL INDEX KEY: 0000872589
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 133444607
STATE OF INCORPORATION: NY
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 777 OLD SAW MILL RIVER ROAD
CITY: TARRYTOWN
STATE: NY
ZIP: 10591
BUSINESS PHONE: 9148477000
MAIL ADDRESS:
STREET 1: 777 OLD SAW MILL RIVER ROAD
CITY: TARRYTOWN
STATE: NY
ZIP: 10591
FORMER COMPANY:
FORMER CONFORMED NAME: REGENERON PHARMACEUTICALS INC
DATE OF NAME CHANGE: 19930328
4
1
edgardoc.xml
PRIMARY DOCUMENT
X0306
4
2020-02-13
0
0000872589
REGENERON PHARMACEUTICALS, INC.
REGN
0001437435
Tessier-Lavigne Marc
777 OLD SAW MILL RIVER ROAD
TARRYTOWN
NY
10591
1
0
0
0
Common Stock
2020-02-13
4
M
0
5000
57.11
A
6830
D
Common Stock
2020-02-13
4
S
0
5000
400.03
D
1830
D
Common Stock
2020-02-13
4
M
0
9279
50.91
A
11109
D
Common Stock
2020-02-13
4
S
0
637
398.71
D
10472
D
Common Stock
2020-02-13
4
S
0
800
399.41
D
9672
D
Common Stock
2020-02-13
4
S
0
7842
400.16
D
1830
D
Non-Qualified Stock Option (right to buy)
50.91
2020-02-13
4
M
0
9279
0.0
D
2021-11-18
Common Stock
9279
0
D
Non-Qualified Stock Option (right to buy)
57.11
2020-02-13
4
M
0
5000
0.0
D
2022-01-03
Common Stock
5000
0
D
Represents volume-weighted average price of sales of 5,000 shares of Company stock on February 13, 2020 at prices ranging from $400.00 to $400.88. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 13, 2020 at each separate price.
Represents volume-weighted average price of sales of 637 shares of Company stock on February 13, 2020 at prices ranging from $398.39 to $398.89. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 13, 2020 at each separate price.
Represents volume-weighted average price of sales of 800 shares of Company stock on February 13, 2020 at prices ranging from $399.00 to $399.85. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 13, 2020 at each separate price.
Represents volume-weighted average price of sales of 7,842 shares of Company stock on February 13, 2020 at prices ranging from $400.02 to $400.86. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 13, 2020 at each separate price.
The stock option becomes exercisable in three equal annual installments, commencing one year after the date of grant.
/s/**Marc Tessier-Lavigne
2020-02-14